CoChat

Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients

Open access
Danthu, Clément, Hantz, Sébastien, Dahlem, Arthur, Duval, Marion, Ba, Bacary, Guibbert, Manon, El Ouafi, Zhour, Ponsard, Séverine, Berrahal, Insaf, Achard, Jean-Michel, Bocquentin, Frédérique, Allot, Vincent, Rerolle, Jean-Philippe, Alain, Sophie, Touré, Fatouma · 2021 · Journal of the American Society of Nephrology
Cited by 164

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Significance Statement: Data are lacking on the humoral response to COVID-19 vaccination in kidney transplant recipients and patients on hemodialysis. This study of humoral response to an mRNA vaccine in 78 patients undergoing hemodialysis, 74 kidney transplant recipients, and seven healthy controls found that anti–SARS-CoV-2 antibodies peaked at day 36 postvaccination among controls, whereas patients on hemodialysis had lower titers that peaked at day 58, and only three patients who received kidney transplant exhibited detectable antibody levels. Among patients on hemodialysis, age <75 years, serum albumin, and Kt/V were positively correlated with serological response; those who were nonresponders to the HBV vaccine had the lowest anti–SARS-CoV-2 antibody titers. These findings suggest that postvaccination humoral response is strongly inhibited by immunosuppressant therapy in kidney transplant recipients and is reduced by the uremic condition in patients on hemodialysis. Background: Kidney transplant recipients and patients receiving hemodialysis are immunocompromised populations that are prioritized for COVID-19 vaccination but were excluded from clinical trials of SARS-CoV-2 mRNA vaccines. Antibody titers and rates of seroconversion after vaccination are lower among patients with CKD and those taking immunosuppressants compared with controls. Data are lacking regarding their humoral response to vaccination to prevent COVID-19. Methods: This investigation of early serological response after COVID-19 vaccination with the Pfizer/BioNTech (BNT162b2) mRNA vaccine included 78 patients undergoing hemodialysis, 74 kidney transplant recipients, and seven healthy controls. We recorded data from the medical file for various clinical parameters, including response to hepatitis B vaccination, and measured antibody titers against SARS-CoV-2 at 0, 14, 28, 36, and 58 days after the first injection. Results: In controls, we detected antibodies at a positive level (>13 arbitrary units per ml; AU/ml) at day 14 postinjection, which increased progressively to peak at day 36 (1082 AU/ml; interquartile range [IQR], 735.0–1662.0). Patients undergoing hemodialysis had lower titers that peaked at day 58 (276 AU/ml; IQR, 83.4–526.0). We detected a positive antibody level in only three transplant recipients at day 36. In patients on hemodialysis, those aged <75 years had a higher antibody response versus those aged >75 years, and serum albumin and Kt/V were positively correlated with serological response (P<0.04 and P<0.0, respectively); nonresponders to HBV vaccine had the lowest anti–SARS-CoV-2 antibody titers. Conclusions: Our results suggest that the postvaccination humoral response is strongly inhibited by immunosuppressant therapy in kidney transplant recipients, and is reduced by the uremic condition in patients undergoing hemodialysis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.2021040490

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 164

Metadata

Authors
Danthu, C., Hantz, S., Dahlem, A., Duval, M., Ba, B., Guibbert, M., El Ouafi, Z., Ponsard, S., Berrahal, I., Achard, J.-M., Bocquentin, F., Allot, V., Rerolle, J.-P., Alain, S., & Touré, F.
Venue
Journal of the American Society of Nephrology
Published
2021-09
Volume
32
Issue
9
Pages
2153-2158
ISSN
  • 1046-6673 (ISSN-L)
  • 1533-3450
OpenAlex
W3166460483
Cited by
164
References
4
FWCI
11.62
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.